Sugi Predict

Sugi Predict / Compounds / SCHEMBL4312243

SCHEMBL4312243

SCHEMBL4312243

O=C(O)C(F)(F)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 0.50
▸ GRB2 P62993 1/20 0.49
▸ TSHR P16473 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ PTGDR2 Q9Y5Y4 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ PPARA Q07869 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ CES2 O00748 2/20 0.41
▸ CES1 P23141 2/20 0.41
▸ PPARG P37231 4/20 0.41
▸ SRD5A2 P31213 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23457137 0.98 MIF (0.48) MIFGRB2TSHRALOX15MEN1
Sulfuric Acid SCHEMBL23457136 0.92 MIF (0.44) MIFGRB2TSHRALOX15MEN1
Phosphoric Acid SCHEMBL23457138 0.92 MIF (0.44) MIFGRB2TSHRALOX15MEN1
SCHEMBL13199203 0.88 GRB2 (0.57) GRB2MEN1KMT2ACYP1A2CYP2C19
SCHEMBL23067415 0.86 MIF (0.43) MIFGRB2TSHRALOX15MEN1
SCHEMBL23067479 0.86 GRB2 (0.42) MIFGRB2TSHRALOX15MEN1
SCHEMBL8255103 0.82 MIF (0.45) MIFTSHRALOX15MEN1KMT2A
SCHEMBL13199251 0.81 GRB2 (0.52) GRB2CES2CES1SRD5A2KDM1A
SCHEMBL23588301 0.81 CES2 (0.56) GRB2TSHRCYP1A2CES2CES1
SCHEMBL16595347 0.81 CYP2A6 (0.41) MIFGRB2TSHRCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111170991-B Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2023-10-31 — — CN claimed
CN-114761004-A Process for the preparation of 2- (4-chlorophenyl) -N- ((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2, 2-difluoroacetamide 细胞基因公司 2022-07-15 — — CN claimed
US-20220213056-A1 PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE CELGENE CORP (US) 2022-07-07 — — US claimed
CN-112608376-B Preparation method of active peptide Apelin 温州医科大学慈溪生物医药研究院 2022-05-20 — — CN claimed
US-11312699-B2 Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide CELGENE CORPORATION (US) 2022-04-26 — — US claimed
CN-112546198-B A pharmaceutical composition for treating cerebral apoplexy and acute cerebral infarction 温州医科大学慈溪生物医药研究院 2022-03-25 — — CN claimed
US-20210171493-A1 PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE CELGENE CORPORATION 2021-06-10 — — US claimed
WO-2021113566-A1 PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE CELGENE CORPORATION (US) 2021-06-10 — — WO claimed
CN-112608376-A Preparation method of active peptide Apelin 温州医科大学慈溪生物医药研究院 2021-04-06 — — CN claimed
CN-111170991-A Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2020-05-19 — — CN claimed
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 — — US claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 — — EP claimed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US claimed
US-9968596-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2018-05-15 — — US claimed
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-01-25 — — US claimed
EP-3114715-A1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS Siemens Aktiengesellschaft (DE) 2017-01-11 — — EP claimed
US-12617762-B2 Carboxy derivatives with antiinflamatory properties SITRYX THERAPEUTICS LIMITED (GB) 2026-05-05 — — US disclosed
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 — — EP disclosed
WO-2002089806-A1 HETEROBICYCLES FKBP-LIGANDS AGOURON PHARMACEUTICALS, INC. (US) 2002-11-14 — — WO disclosed
US-5583147-A INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL O-TRANSFERASE; ANTIHYPERCHOLESTEROLEMIC AND/OR ANTIATHEROSCLEROTIC AGENTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171493-A1 PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE DCPS, DNMT1, DPYD MIF 4178/4885GRB2 1282/4885TSHR 4169/4885
US-20220213056-A1 PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE DCPS, DNMT1, DPYD MIF 4178/4885GRB2 1282/4885TSHR 4169/4885
US-11312699-B2 Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide DCPS, DNMT1, DPYD MIF 4178/4885GRB2 1282/4885TSHR 4169/4885
US-12617762-B2 Carboxy derivatives with antiinflamatory properties CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MIF 204/4885GRB2 3652/4885TSHR 3443/4885
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX MIF 392/4885GRB2 1203/4885TSHR 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.